Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.

Journal of thrombosis and haemostasis : JTH - 1 May 2012

Mancuso M E, Mannucci P M, Rocino A, Garagiola I, Tagliaferri A, Santagostino E

Abstract excerpt

BACKGROUND: Inhibitor development is influenced by several factors and the type of factor VIII (FVIII) products may play a role. OBJECTIVES: In order to explore such a role, we designed a cohort study whose novelty resides in the classification of products not only according to the source of FVII...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Coagulants
Share to Factor VIII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia A

Share to Proportional Hazards Models

Share to Recombinant Proteins

Share to Risk Assessment

Source

Identifiers

PMID: 22452823
DOI: 10.1111/j.1538-7836.2012.04691.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22452823-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.PMID 22452823Read ↗

Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesSemantic proximity Read ↗

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.Semantic proximity Read ↗

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.Semantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.Semantic proximity Read ↗

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.Semantic proximity Read ↗

Key insights to understand the immunogenicity of FVIII products.Semantic proximity Read ↗

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.Semantic proximity Read ↗

SIPPET: methodology, analysis and generalizabilitySemantic proximity Read ↗

Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A.Semantic proximity Read ↗

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.Semantic proximity Read ↗

Biological considerations of plasma-derived and recombinant factor VIII immunogenicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.